<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899665</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000483773</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-2111</secondary_id>
    <secondary_id>WSU-12-35-99(M02)</secondary_id>
    <nct_id>NCT00899665</nct_id>
  </id_info>
  <brief_title>Proteases in Patients With Prostate Cancer That Has Spread to the Bone</brief_title>
  <official_title>Proteases in Prostate Cancer Bone Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting and storing samples of bone marrow and tissue from patients to test in
      the laboratory may help the study of cancer.

      PURPOSE: This laboratory study is comparing proteases (enzymes that break down protein) in
      patients with prostate cancer that has spread to the bone with patients who do not have
      cancer that has spread to the bone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Examine the roles of proteases and protease-associated molecules in bone metastases in
           patients with metastatic prostate cancer.

      OUTLINE: Patients undergo bone marrow aspiration and core bone biopsies. Tissues are analyzed
      by immunohistochemistry methods, in situ hybridization assays, gelatin zymography and/or
      Western blot analysis, and gene profiling analysis in order to visualize and quantitate
      protease or protease-related levels.

      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Expression and activity of proteases and related molecules</measure>
  </primary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Anemia</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Precancerous Condition</condition>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>molecular diagnostic method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immunoscintigraphy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets 1 of the following criteria:

               -  Diagnosis of metastatic prostate cancer

                    -  Patients with documented bone metastases on radiologic imaging studies must
                       undergo bone marrow biopsy

               -  Male patients ≥ 50 years of age without cancer who are scheduled to undergo bone
                  biopsy for other clinically indicated reasons, including any of the following:

                    -  Myelodysplasia

                    -  Anemia

                    -  Monoclonal gammopathy of undetermined significance

               -  Male or female patients ≥ 40 years of age without metastatic bone cancer who are
                  scheduled to undergo an orthopedic procedure involving removal of bone specimen

        PATIENT CHARACTERISTICS:

          -  See Disease Characteristics

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L. Cher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>bone metastases</keyword>
  <keyword>anemia</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

